Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Relay Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Relay Therapeutics, Inc.

RLAY

Relay Therapeutics, Inc.

About Relay Therapeutics, Inc.

Relay Therapeutics is a biopharmaceutical company specializing in precision medicine through its Dynamo platform, which integrates computational and experimental techniques to target previously intractable proteins. Its focus includes oncology and genetic diseases, developing small molecule therapies such as mutant-selective kinase inhibitors. The company advances pipeline candidates, collaborates with partners like Pfizer and Elevar, and aims to deliver targeted, innovative treatments for life-threatening conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Relay Therapeutics, Inc.

1
1
Relay Therapeutics, Inc. Relay Therapeutics Reports $3 Million Revenue and $73.3 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Relay Therapeutics, Inc. Relay Therapeutics Reports $276.5M Net Loss and $15.4M Revenue for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Relay Therapeutics, Inc. Relay Therapeutics Reports $74.1 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Relay Therapeutics, Inc. Relay Therapeutics Reports Q2 2025 Financial Results with $677,000 Revenue and $70.4 Million Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Relay Therapeutics, Inc. Relay Therapeutics Reports Q1 2025 Revenue Decline to $7.7 Million, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Relay Therapeutics, Inc. Relay Therapeutics Reports Decline in Revenue, Net Loss, and Updates on Clinical Programs and Funding

Via official filing (AI summary) | over 1 year ago | 0 comments